Gepants for Migraine: Rimegepant Leads in Cost-Effectiveness
- MigraineMind
- Nov 26, 2025
- 1 min read
Research Summary
A recent study in the American Journal of Managed Care analyzed the cost-effectiveness of three small-molecule CGRP receptor antagonists—ubrogepant, rimegepant, and zavegepant—for acute migraine treatment compared to usual care. These treatments, known as gepants, are considered third-line options for patients who do not respond to first- and second-line therapies. Using a Markov model over a 5-year period, researchers found that none of the gepants were cost-effective at willingness-to-pay thresholds of $50,000, $100,000, or $150,000 per QALY. However, rimegepant emerged as the most cost-effective choice, offering a better balance of cost and effectiveness than its counterparts.
Study Details
👥 Research Team: Gokhale P, Villa Zapata L
📚 Published In: Am J Manag Care
📅 Publication Date: 2025 Nov 1
⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.